Table 1.
Demographic data of 7 patients
| Patient No. | Age (yr)/Sex | Latent time (mo) | GTV (mL) | Dose (Gy) | Prescribed isodose (%) | Dmax of intestine (Gy) | V45 (mL) | Failure pattern | F/U (mo) | Final status |
| 1 | 63/M | 9 | 20 | 36 | 83 | 33 | 0 | Lt SCLN (23) | 70 | AWD |
| Lung (32) | ||||||||||
| 2 | 64/F | 44 | 4 | 41 | 82 | 38 | 0 | - | 37 | Died due to lymphoma |
| 3 | 52/F | 29 | 24 | 45 | 78 | 48 | 0.2 | Spine (26) | 41 | DOD |
| 4 | 59/M | 21 | 22 | 48 | 80 | 51 | 0.7 | Lung (7) | 22 | DOD |
| 5 | 56/M | 10 | 9 | 48 | 80 | 40 | 0 | PALN(9) | 21 | AWD |
| 6 | 47/M | 18 | 40 | 48 | 76 | 53 | 3.6 | Rectum (7) | 25 | DOD |
| Lt SCLN (7) | ||||||||||
| Peritoneal seeding (25) | ||||||||||
| Local recur (13) | ||||||||||
| 7 | 73/M | 7 | 29 | 51 | 78 | 50 | 0.9 | - | 26 | CDF |
GTV: Gross tumor volume; AWD: Alive with disease; CDF: Continuously disease-free; DOD: Died of disease; Latent time: Disease free interval from operation to first relapse; F/U: Follow-up from commencement of SBRT to last follow-up or death; Lt SCLN: Left supraclavicular lymph node; Dmax: Maximum point dose of intestine; V45: Intestinal volume receiving 45 Gy or more; Vpre: Total volume receiving the prescribed dose or more; Parenthesis (mo) means the period from SBRT to detection of complication.